FindTrial
Sign In

A Study to Evaluate the Efficacy and Safety of AD-208

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04825561
Enrollment
139
Registered
2021-04-01
Start date
2021-06-09
Completion date
2023-06-01
Last updated
2023-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic Alopecia

Brief summary

The purpose of this study is to evaluate the efficacy and safety of AD-208.

Detailed description

The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.

Interventions

DRUGAD-208

PO, Once daily(QD), 24weeks

DRUGAD-2081

PO, Once daily(QD), 24weeks

DRUGplacebo of AD-208

PO, Once daily(QD), 24weeks

DRUGplacebo of AD-2081

PO, Once daily(QD), 24weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Male patients aged 18-50 years, inclusive * Patients who meet the appropriate criteria according to the classification of hair loss * Signed informed consent

Exclusion criteria

* Patients with hair loss disorders other than androgenetic alopecia * Other exclusions applied

Design outcomes

Primary

MeasureTime frameDescription
The amount of Change in the total number of hairsBaseline, Week 24The amount of change in the total number of hairs in the unit area

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026